<DOC>
	<DOC>NCT02445911</DOC>
	<brief_summary>This study will consist of multiple ascending oral doses in up to 3 groups, for 29 days.</brief_summary>
	<brief_title>Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Ascending Doses of KQ-791 in Diabetes Mellitus</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<criteria>Have a diagnosis of Type 2 Diabetes Mellitus (T2DM) Be an adult between the ages of 18 (19 for Lincoln site) and 70 years Female participants must be of nonchildbearing potential, and must be either 1) postmenopausal with amenorrhea for at least 1 year prior to the first dose and Follicle Stimulating Hormone (FSH) serum levels consistent with postmenopausal status, or 2) have undergone one of the following sterilization procedures at least 6 months prior to the first dose: hysteroscopic sterilization bilateral tubal ligation or bilateral salpingectomy hysterectomy bilateral oophorectomy Nonvasectomized males must agree to use a condom with spermicide or abstain from sexual intercourse during the study until 100 days beyond the last dose of study drug. (No restrictions are required for a vasectomized male provided his vasectomy has been performed 4 months or more prior to first dosing. A male who has been vasectomized less than 4 months prior to first dosing must follow the same restrictions as a nonvasectomized male) Males must agree to not donate sperm during the study and for 100 days following the last dose Have an HbA1c value between 7.010.0% Be on a stable treatment regimen of metformin, with or without diet/exercise, for at least 8 weeks Weigh 60 kilograms (kg) or more at screening and have a body mass index (BMI) greater than or equal to (≥) 25.0 and less than or equal to (≤) 40.0 kilograms/meters squared (kg/m2) Have laboratory test results within the normal range for T2DM population, or with abnormalities deemed clinically insignificant. Urine protein levels must be within normal limits Absence of active diabetic retinopathy (Stage 2 or greater by the International Clinical Disease Severity Scale for Diabetic Retinopathy) Are willing to comply with specific dietary restrictions (that is, [i] able to fast overnight for at least 812 hours on several days and [ii] able to consume the standard meals provided during specified confinement days) Have given written consent to allow collection of samples for Peripheral Blood Mononuclear Cells (PBMC) analysis and for possible biomarkers/safety analysis Have given written informed consent approved by the institutional review board (IRB) governing the site Are currently enrolled in a clinical trial involving an investigational product or offlabel use of a drug or device, or are concurrently enrolled in any other type of medical research judged not to be scientifically or medically compatible with this study Participated (defined as the last dose of study drug) within 30 days prior to dosing in a clinical trial involving an investigational product or nonapproved use of a drug with a short halflife or within 5 halflives of an investigational product with a halflife longer than 6 days Have a (QTcF) greater than (&gt;) 450 milliseconds (msec), or clinical significant hypokalemia, a family history of long QT syndrome or any abnormality in the 12lead Electrocardiogram (ECG) Abnormal blood pressure (sitting) defined as diastolic blood pressure &gt; 95 or less than (&lt;) 50 millimeter of mercury (mmHg) and/or systolic blood pressure &gt; 160 or &lt; 90 mmHg Have a history or presence of cardiovascular, respiratory, hepatic, renal, gastrointestinal, endocrine, hematological, or neurological disorders capable of significantly altering the absorption, metabolism, or elimination of drugs Show evidence of regular use of known drugs of abuse and/or positive findings on urinary drug screening Evidence of human immunodeficiency virus (HIV) infection, hepatitis B, hepatitis C and/or positive results at screening for the respective antibodies for HIV, hepatitis B surface antigen (HBsAg), or hepatitis C antibodies (HCV) Have anemia that would interfere with the trial or have donated ≥500 mL of blood within 56 days before the first dose or have donated plasma within 7 days before the first dose or provided any blood donation within last 30 days Have an average weekly alcohol intake that exceeds 14 units per week (males) and 7 units per week (females) [1 unit = 12 ounces (oz) or 360 mL of beer, 5 oz or 150 mL of wine, or 1.5 oz or 45 mL of distilled spirits] or are unwilling to stop alcohol consumption 48 hours prior to the first dosing and throughout the study Consume more than 10 cigarettes per day or the equivalent or are unable or unwilling to adhere to restricted smoking policies Have had &gt;1 episode of documented severe hypoglycemia within last 6 months or are currently diagnosed as having hypoglycemia unawareness Have any of the following clinical laboratory test results: estimated glomerular filtration rate (eGFR) &lt; 60 mL/min/1.73 m2 (impaired renal function) alanine aminotransferase (ALT) or aspartate aminotransferase (AST) levels &gt; 1.5 times (x) the upper limit of normal (ULN) triglycerides (TG) &gt; 500 milligrams/deciliter (mg/dL) Have used insulin or other glycemic control medications, except metformin, for diabetic control within 3 months Intend to use nonsteroidal antiinflammatory drugs (except aspirin) and drugs known to prolong QT interval, herbal products, or vitamin supplements that change glucose levels. The following medications are allowed for participants: drugs for treatment of hypertension or lipid disorders (except bile acid resins, niacin or fish oils), platelet inhibitors, and on stable dose for 12 weeks prior to first dose thyroid replacement therapy, proton pump inhibitors, antidepressants, antihistamines, regularly taken overthecounter (OTC) and antiemetics that do not cause a corrected QT interval (QTc) prolongation, provided such drugs are not specifically excluded hormonal replacement therapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>September 2016</verification_date>
</DOC>